Loading
A phase 2 trial of atezolizumab and temozolomide in lung cancer, run by Dwight Owen, now recruiting.
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT04919382 by Dwight Owen, with a registry enrolment figure of 56 participants, started 2022-01-26 and due to reach its primary completion in 2027-12-30. Interventions recorded: Atezolizumab; Temozolomide. Conditions listed: Extensive Stage Lung Small Cell Carcinoma; Metastatic Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8. Primary outcome: Investigator-assessed objective response rate (ORR). Lung eligibility wording from the registry: "metastatic and/or recurrent) small cell lung cancer and have progressed or recurred after platinum-based chemotherapy with immunotherapy". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/